Oncologists from NYP, CUMC and WCMPresent at ASCO Annual Meeting

May 27, 2016

Oncologists from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will discuss their latest research findings at the American Society for Clinical Oncology (ASCO) annual meeting, June 3-7 in Chicago. The presentations will cover a variety of disciplines and treatment approaches, with a focus on this year's meeting theme: the future of patient-centered care and research.

Among the institutions' total of 48 sessions, two abstracts have been selected for inclusion in the Best of ASCO program, which highlights the most cutting-edge science and research presented at the meeting. Dr. Dawn Hershman, leader of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Medical Center, will discuss the risk of neuropathy in patients receiving chemotherapy, and Dr. Adrienne Phillips, assistant professor of medicine at Weill Cornell Medicine and assistant attending physician at NewYork-Presbyterian/Weill Cornell Medical Center, will present information about a novel antibody that combats CCR4 in adult T-cell lymphoma.

For the full schedule and updates throughout the meeting, please visit nyp.org/asco.

Among the most significant participants and presentations this year are the following:

Friday, June 3

Dr. Jennifer Levine
Oral Abstract Session: Pediatric Oncology
Nonsurgical premature menopause in the Childhood Cancer Survivor Study: prevalence, risk factors and reproductive outcomes (Abstract 10504)
4:12 - 4:24 p.m., S504

Saturday, June 4

Dr. Manish A. Shah
The BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo + weekly paclitaxel in patients with pretreated advanced gastric and gastro-esophageal junction adenocarcinoma (Abstract TPS4144)
8:00 - 11:30 a.m.; Hall A, Poster Board: #129b

Dr. Naiyer A. Rizvi
Poster Discussion Session: Lung Cancer--Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Immunotherapy in Rare Thoracic Malignancies (Abstracts 8517, 8518, 8519)
2:09 - 2:21 p.m., Arie Crown Theater

Sunday, June 5

Dr. Dawn L. Hershman
Best of ASCO: Patient and Survivor Care
Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants in SWOG clinical trials (Abstract 10001)
8:12 - 8:24 a.m., S102

Dr. Heather Greenlee
Oral Abstract Session: Patient and Survivor Care
Body mass index, lifestyle factors, and taxane-induced neuropathy in women with breast cancer: The Pathways Study (Abstract 10002)
8:24 - 8:36 a.m., S102

Dr. Alan Astrow
Oral Abstract Session: Patient and Survivor Care
Just what are spiritual needs of cancer patients? An empirical study in a diverse population (Abstract 10005)
9:24 - 9:36 a.m., S102

Dr. Adrienne Phillips
Best of ASCO: Hematologic Malignancies--Lymphoma and Chronic Lymphocytic Leukemia
A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice in the treatment of patients with relapsed/refractory adult t-cell leukemia-lymphoma (Abstract 7501)
9:57 - 10:09 a.m., E354b

Monday, June 6

Dr. Scott T. Tagawa
Oral Abstract Session: Genitourinary (Prostate) Cancer
TAXYNERGY: Randomized trial of early switch from first-line docetaxel to cabazitaxel or vice versa with circulating tumor cell biomarkers in patients with metastatic castration-resistant prostate cancer (Abstract 5007)
10:12 - 10:24 a.m., Hall D2

NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine offer state-of-the-art care at three of the nation's leading cancer centers: the National Cancer Institute-designated Herbert Irving Comprehensive Cancer Center of NewYork-Presbyterian/Columbia University Medical Center, the NewYork-Presbyterian/Weill Cornell Ronald P. Stanton Clinical Cancer Program and the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.

NewYork-Presbyterian is one of the nation's most comprehensive healthcare delivery networks, focused on providing innovative and compassionate care to patients in the New York metropolitan area and throughout the globe. In collaboration with two renowned medical school partners, Weill Cornell Medicine and Columbia University College of Physicians & Surgeons, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research and clinical innovation.

NewYork-Presbyterian has four major divisions: NewYork-Presbyterian Hospital is ranked #1 in the New York metropolitan area by U.S. News and World Report and repeatedly named to the magazine's Honor Roll of best hospitals in the nation; NewYork-Presbyterian Regional Hospital Network is comprised of leading hospitals in and around New York and delivers high-quality care to patients throughout the region; NewYork-Presbyterian Physician Services connects medical experts with patients in their communities; and NewYork-Presbyterian Community and Population Health features the hospital's ambulatory care network sites and operations, community care initiatives and healthcare quality programs, including NewYork Quality Care, established by NewYork-Presbyterian, Weill Cornell and Columbia.

NewYork-Presbyterian is one of the largest healthcare providers in the U.S. Each year, nearly 29,000 NewYork-Presbyterian professionals deliver exceptional care to more than 2 million patients.

For more information, visit http://www.nyp.org and find us on Facebook, Twitter and YouTube.

Columbia University Medical Center

Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.

Weill Cornell Medicine

Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world. The doctors and scientists of Weill Cornell Medicine -- faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization -- are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. Located in the heart of the Upper East Side's scientific corridor, Weill Cornell Medicine's powerful network of collaborators extends to its parent university Cornell University; to Qatar, where an international campus offers a U.S. medical degree; and to programs in Tanzania, Haiti, Brazil, Austria and Turkey. Weill Cornell Medicine faculty provide comprehensive patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian/Lower Manhattan Hospital and NewYork-Presbyterian/Queens. Weill Cornell Medicine is also affiliated with Houston Methodist. For more information, visit weill.cornell.edu.

Weill Cornell Medicine

Related Neuropathy Articles from Brightsurf:

Identified the cellular process by which Cisplatin chemotherapy causes neuronal damage
Cisplatin induces senescence of peripheral neurons through overexpression of the p21 protein, which would explain the neuropathy.

Penn researchers identify new genetic cause of a form of inherited neuropathy
Inherited mutations in a gene that keeps nerve cells intact was shown, for the first time, to be a driver of a neuropathy known as Charcot-Marie-Tooth disease.

NUS researchers identify novel protein to prevent neuropathy from chemotherapy
A team of researchers from the NUS Yong Loo Lin School of Medicine has identified a novel protein that would prevent the development of neuropathy, a major side effect of chemotherapy, in cancer patients.

Poor diet can lead to blindness
An extreme case of 'fussy' or 'picky' eating caused a young patient's blindness, according to a new case report published today [2 Sep 2019] in Annals of Internal Medicine.

Genetic marker linked to increased risk of diabetic peripheral neuropathy
This is the first real effort to have a genome wide search for genes predisposing to diabetic peripheral neuropathy.

Healthy fats improve nerve function in obese mice
Swapping dietary saturated fats for monounsaturated fats reverses nerve damage and restores nerve function in male mice, finds new preclinical research published in JNeurosci.

Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer
A new study assesses chemotherapy-induced peripheral neuropathy in 121 long-term survivors of childhood cancer to detail clinical, functional, neurophysiological and patient-reported outcomes of the condition.

Diagnosing, treating neuropathy symptoms in cancer patients not exact science
Most of the roughly 15.5 million cancer survivors in the US receive chemotherapy, and roughly 65 percent develop some degree of the chemotherapy-induced nerve damage known as peripheral neuropathy.

MDI Biological Laboratory discovery could lead to new therapies for diabetics
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy also plays a role in peripheral neuropathy caused by diabetes.

Researchers test first drug to prevent the onset of chemotherapy-induced neuropathy
Peripheral neuropathy is a very common side-effect of chemotherapy and may eventually lead to early discontinuation of treatment.

Read More: Neuropathy News and Neuropathy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.